The ISAQ Score Does Not Predict Adrenal Crisis in Patients with Primary Adrenal Insufficiency

Abstract

Objective This study aimed to investigate the ability of the immune system assessment questionnaire (ISAQ) to predict adrenal crisis (AC) and infectious events in patients with primary adrenal insufficiency (PAI).

Design This was a prospective single-centre study over three years.

Methods Patients answered the ISAQ at baseline and were seen every 4–6 months in the endocrine outpatient clinic. At each visit previous infectious periods which required an increase in daily glucocorticoid dosage and AC were reported and documented. Seventy-five patients with PAI (53 women; 43 patients with autoimmune PAI, 20 patients with salt-wasting congenital adrenal hyperplasia and 12 patients who underwent bilateral adrenalectomy) were analysed. Due to the COVID-19 pandemic and consecutive lockdown measures, the data were analysed separately for March 2018 to March 2020 (period 1), and March 2020 to March 2021 (period 2).

Results During period 1 the ISAQ score significantly correlated with the number of reported infectious events (r=0.351; p<0.01), but not during period 2 (r=0.059, p=0.613), in which the number of infectious events per patient-year significantly decreased (1.1±0.1 vs 0.4±0.1; p<0.001). The frequency of AC decreased from 8.8 to 2.4 per 100 patient-years between the two study periods. The ISAQ score was not different between patients with or without AC.

Conclusions The ISAQ score does not identify patients prone to ACs. The COVID-19 pandemic and consecutive lockdown measures significantly diminished the frequency of infectious events and ACs.

Key words

Addison’s disease - ISAQ score - AddiQoL - adrenal crisis - COVID-19 - congenital adrenal hyperplasia

Publication History

Received: 29 October 2021
Received: 12 December 2021

Accepted: 04 January 2022

Article published online:
03 March 2022

• References

• 1 Hahner S, Loeffler M, Fassnacht M. et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 2007; 92: 3912-3922
• 2 Bergthorsdottir R, Leonsson-Zachrisson M, Oden A. et al. Premature mortality in patients with Addison’s disease: A population-based study. J Clin Endocrinol Metab 2006; 91: 4849-4853
• 3 Erichsen MM, Lovas K, Skinningsrud B. Wolff ABet al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: Observations from a Norwegian registry. J Clin Endocrinol Metab 2009; 94: 4882-4890
• 4 Bornstein SR, Allolio B, Arlt W. et al. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2016; 101: 364-389
• 5 Hahner S, Ross RJ, Arlt W. et al. Adrenal insufficiency. Nat Rev Dis Primers 2021; 7: 19
• 6 Hahner S, Loeffler M, Bleicken B. et al. Epidemiology of adrenal crisis in chronic adrenal insufficiency: The need for new prevention strategies. Eur J Endocrinol 2010; 162: 597-602
• 7 Smans LC, Van der Valk ES, Hermus AR. et al. Incidence of adrenal crisis in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2016; 84: 17-22
• 8 Meyer G, Neumann K, Badenhoop K. et al. Increasing prevalence of Addison’s disease in German females: Health insurance data 2008-2012. Eur J Endocrinol 2014; 170: 367-373
• 9 Meyer G, Badenhoop K, Linder R. Addison’s disease with polyglandular autoimmunity carries a more than 2 5-fold risk for adrenal crises: German health insurance data 2010-2013. Clin Endocrinol (Oxf) 2016; 85: 347-353
• 10 Reisch N, Willige M, Kohn D. et al. Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. Eur J Endocrinol 2012; 167: 35-42
• 11 Hahner S, Spinnler C, Fassnacht M. et al. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: A prospective study. J Clin Endocrinol Metab 2015; 100: 407-416
• 12 Quinkler M, Murray RD, Zhang P. et al. Characterization of patients with adrenal insufficiency and frequent adrenal crises. Eur J Endocrinol 2021; 184: 761-771
• 13 White K, Arlt W. Adrenal crisis in treated Addison’s disease: A predictable but under-managed event. Eur J Endocrinol 2010; 162: 115-120
• 14 Ono Y, Ono S, Yasunaga H. et al. Clinical features and practice patterns of treatment for adrenal crisis: A nationwide cross-sectional study in Japan. Eur J Endocrinol 2017; 176: 329-337
• 15 Smans LC, Souverein PC, Leufkens HG. et al. Increased use of antimicrobial agents and hospital admission for infections in patients with primary adrenal insufficiency: A cohort study. Eur J Endocrinol 2013; 168: 609-614
• 16 Peter H-H, Goldacker S, Haraldseide J. et al. Construction and clinical validation of a questionnaire-based risk score to identify patients suffering from immunodeficiency or systemic autoimmunity. British Journal of Medicine & Medical Research 2014; 4(29): 4751-4769
• 17 Isidori AM, Venneri MA, Graziadio C. et al. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): A single-blind, randomised controlled trial. Lancet Diabetes Endocrinol 2018; 6: 173-185
• 18 Reincke M, Ritzel K, Oßwald A. et al. A critical reappraisal of bilateral adrenalectomy for ACTH-dependent Cushing’s syndrome. Eur J Endocrinol 2015; 173: M23-M32
• 19 Ali SR, Bryce J, Haghpanahan H. et al. Real-world estimates of adrenal insufficiency-related adverse events in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2021; 106: e192-e203
• 20 Allolio B. Extensive expertise in endocrinology. Adrenal crisis. Eur J Endocrinol 2015; 172: R115-R124
• 21 Castell S, Akmatov MK, Obi N. et al. Test-retest reliability of an infectious disease questionnaire and evaluation of self-assessed vulnerability to infections: Findings of Pretest 2 of the German National Cohort. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2014; 57: 1300-1307
• 22 Sievers C, Akmatov MK, Kreienbrock L. et al. Evaluation of a questionnaire to assess selected infectious diseases and their risk factors: Findings of a multicenter study. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2014; 57: 1283-1291
• 23 Løvås K, Curran S, Oksnes M. et al. Development of a disease-specific quality of life questionnaire in Addison’s disease. J Clin Endocrinol Metab 2010; 95: 545-551
• 24 Øksnes M, Bensing S, Hulting AL. et al. Quality of life in European patients with Addison’s disease: Validity of the disease-specific questionnaire AddiQoL. J Clin Endocrinol Metab 2012; 97: 568-576
• 25 Bratland E, Skinningsrud B, Undlien DE. et al. T cell responses to steroid cytochrome P450 21-hydroxylase in patients with autoimmune primary adrenal insufficiency. J Clin Endocrinol Metab 2009; 94: 5117-5124
• 26 Koniaris LG, Wand G, Wright TM. TNF mediates a murine model of Addison’s crisis. Shock 2001; 15: 29-34
• 27 Bancos I, Hazeldine J, Chortis V. et al. Primary adrenal insufficiency is associated with impaired natural killer cell function: A potential link to increased mortality. Eur J Endocrinol 2017; 176: 471-480
• 28 Robert Koch-Institut. Surveillance of Influenza in Germany Season 2020/2021. https://influenza.rki.de/Diagrams.aspx?agiRegion=0
• 29 Paul-Ehrlich Institut. Cumulative Number of Released Doses of Infleunza Vaccines in Germany. https://www.pei.de/DE/arzneimittel/impfstoffe/influenza-grippe/vorsaisons/influenza-saisonal-2020-2021-inhalt.htmljsessionid=74C6C95E208A35EA47575974DBDB2E37.intranet211?nn=175430
• 30 Flaxman S, Mishra S, Gandy A. et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 2020; 584: 257-261
• 31 Zhang R, Li Y, Zhang AL. et al. Identifying airborne transmission as the dominant route for the spread of COVID-19. Proc Natl Acad Sci U S A 2020; 117: 14857-14863
• 32 Carosi G, Morelli V, Del Sindaco G. et al. Adrenal insufficiency at the time of COVID-19: A retrospective study in patients referring to a tertiary center. J Clin Endocrinol Metab 2021; 106: e1354-e1361
• 33 Castinetti F, Amodru V, Brue T. Adrenal crisis may occur even in patients with asymptomatic COVID-19. Endocr Pract 2020; 26: 929-930
• 34 Martino M, Aboud N, Cola MF. et al. Impact of COVID-19 pandemic on psychophysical stress in patients with adrenal insufficiency: The CORTI-COVID study. J Endocrinol Invest 2021; 44: 1075-1084
• 35 Arlt W, Baldeweg SE, Pearce SHS. et al. Endocrinology in the time of COVID-19: Management of adrenal insufficiency. Eur J Endocrinol 2020; 183: G25-G32
• 36 Tresoldi AS, Sumilo D, Perrins M. et al. Increased infection risk in Addison’s disease and congenital adrenal hyperplasia. J Clin Endocrinol Metab 2020; 105: 418-429
• 37 Quinkler M, Ekman B, Marelli C. et al. Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency. Endocr Connect 2017; 6: 1-8
• 38 Rivkees SA, Crawford JD. Dexamethasone treatment of virilizing congenital adrenal hyperplasia: The ability to achieve normal growth. Pediatrics 2000; 106: 767-773